Quality and Regulatory Sourcebook eBook
Read the article:
Phase-appropriate Analytical Methodology
Read the eBook:
Pharmaceutical Technology’s Quality and Regulatory Sourcebook eBook
A phase-appropriate analytical development strategy is crucial, especially for complex (formulated) drug substances.
Murrstock - Stock.adobe.com
Progressing a drug candidate from research to commercialization requires huge sums of money (approximately US$1.5 billion–$4.5 billion) (1) and is inherently high risk due to the high attrition rate. Only approximately
10% of total drug attrition is because of poor strategic planning or a lack of commercial needs (2). Highlighting solid strategy and funding alone is not enough to take a drug to market. Approximately 70–80% of clinical failures can be attributed to a lack of clinical efficacy or toxicity (3),
and the majority of drug failures occurring in pre-clinical and Phase I are due to pharmacokinetics or toxicity issues (4).
Read the article:
Phase-appropriate Analytical Methodology
Read the eBook:
Pharmaceutical Technology’s Quality and Regulatory Sourcebook eBook
Read this article in Pharmaceutical Technology's March 2023 Quality and Regulatory Sourcebook eBook.
Paul Van Tilborg is director of analytical sciences at Ardena.
Pharmaceutical Technology
eBook: Quality and Regulatory Sourcebook
March 2023
Pages: 4-6
When referring to this article, please cite it as Van Tilborg, P. Phase-appropriate Analytical Methodology. Pharmaceutical Technology's Quality and Regulatory Sourcebook eBook (March 2023).
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.